Please login to the form below

Not currently logged in
Email:
Password:

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo

Keytruda

Merck & Co. has gained approval for Keytruda for use in third line treatment of small cell lung cancer (SCLC).

Unusually for the runaway leader in the PD-1/PD-L1 immunotherapy field, Keytruda is playing catch up with its rivals in this tumour type, where BMS’ Opdivo is already approved as a third line therapy in SCLC, with Roche’s Tecentriq gaining a prized first line indication in March.

Analysts forecast this lead could help Roche generate $1.5bn in sales from the indication - but one that Merck has its eyes on.

Keytruda can now be used as a monotherapy for small-cell lung cancer patients (SCLC) who have progressed after platinum-based chemotherapy or other prior lines of treatment.

The drug’s approval was fast-tracked by the FDA following the results of its KEYNOTE-158 and KEYNOTE-028 trials. These trials showed that when Keytruda was given as monotherapy to SCLC patients whose cancer had progressed despite prior therapies, they had an objective response rate (ORR) of 19%.

Bearing in mind the normal caveats about comparing such studies, Keytruda’s KEYNOTE-158 and -028 trials suggest a small but significant advantage over Opdivo in overall response rate.

Merck is already exploring Keytruda’s use in combination with chemotherapy in a phase 3 KEYNOTE-604 study. This study focuses on recently-diagnosed patients with advanced-stage SCLC, which would put it in more direct competition with Tecentriq.

EvaluatePharma forecasts that Keytruda will be the top selling drug worldwide in 2024, with predicted sales of 17bn, its lead in non-small cell lung cancer (NSCLC) being the primary driver of this expected success.

Keytruda has also recently been filed as a first-line treatment for head and neck cancer, for use as a monotherapy and in combination with chemotherapy.

Article by
Lucy Parsons

19th June 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics